Correction to ‘ACIP releases 2024 Adult Immunization Schedule featuring new vaccines’

In the Jan. 16, 2024, issue of I.M. Matters Weekly from ACP, the article on the Advisory Committee on Immunization Practices' (ACIP) 2024 Adult Immunization Schedule incorrectly summarized the recommendations for respiratory syncytial virus (RSV) vaccination.

The correct information is as follows:

For patients ages 60 years and older, any approved RSV vaccine can be administered, and vaccination should be based on shared decision making, considering any risk factors for severe RSV disease, risk of exposure to RSV, and preferences for RSV vaccination. In pregnant patients, ACIP notes that only Pfizer's RSV vaccine (Abrysvo) is recommended; it should be given during 32 through 36 weeks' gestation from September through January in most of the continental U.S, ACIP said.

Last week's article has been updated.